192702-01-5

Basic information

• Product Name: 3-CHLORO-4-FLUOROBENZYL BROMIDE
• Synonyms: 3-CHLORO-4-FLUOROBENZYL BROMIDE;alpha-Bromo-3-chloro-4-fluorotoluene;à-bromo-3-chloro-4-fluorotoluene;3-Chloro-4-fluorobenzyl bromide 97%;3-Chloro-4-fluorobenzylbromide97%;-Bromo-3-Chloro-4-Fluorotoluene;4-(BroMoMethyl)-2-chloro-1-fluorobenzene;alpha-Bromo-3-chloro-4-fluorotoluene 1-(Bromomethyl)-3-chloro-4-fluorobenzene
• CAS NO: 192702-01-5
• Molecular Formula: C₇H₅BrClF
• Molecular Weight: 223.47
• EINECS: -0
• Product Categories: Aromatic Halides (substituted);Fluorine series
• Mol File: 192702-01-5.mol

Chemical Properties

• Boiling Point: 63-65°C 0,6mm
• Flash Point: 63-65°C/0.6mm
• Appearance: /
• Density: 1.653 g/mL at 25 °C
• Vapor Pressure: 0.0784mmHg at 25°C
• Refractive Index: 1.568
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Sensitive: Lachrymatory
• BRN: 2435145
• CAS DataBase Reference: 3-CHLORO-4-FLUOROBENZYL BROMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: 3-CHLORO-4-FLUOROBENZYL BROMIDE(192702-01-5)
• EPA Substance Registry System: 3-CHLORO-4-FLUOROBENZYL BROMIDE(192702-01-5)

Safety Data

• Hazard Codes: C,Xn
• Statements: 34-36/37/38-22
• Safety Statements: 26-36/37/39-45
• RIDADR: 3265
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 192702-01-5(Hazardous Substances Data)

Usage

Chemical Properties

Liquid

InChI:InChI=1/C7H5BrClF/c8-4-5-1-2-7(10)6(9)3-5/h1-3H,4H2

Upstream product

• 34328-61-5 3-Chloro-4-fluorobenzaldehyde 
• 161446-90-8 3-chloro-4-fluorobenzyl alcohol 
• 452-84-6 3-amino-4-fluorotoluene 
• 1513-25-3 2-chloro-1-fluoro-4-methylbenzene 

Downstream Products

• 870006-84-1 (6S)-4-amino-2-(3-chloro-4-fluorobenzyl)-10-methoxy-8-ethyl-6-methyl-7,8-dihydropyrazino[1',2':1,5]pyrrolo[2,3-d]pyridazine-1,9(2H,6H)-dione 
• 865300-49-8 1-(3-chloro-4-fluorobenzyl)piperidin-2-one 
• 851726-46-0 tert-butyl 4-(3-chloro-4-fluorobenzyl)-3-oxopiperazine-1-carboxylate 
• 658-98-0 2-(3-chloro-4-fluorophenyl)acetonitrile 
• 1440519-55-0 N-[2-(3-chloro-4-fluoro-phenyl)-ethyl]-2,2,2-trifluoro-acetamide 
• 244194-67-0 2-(3-chloro-4-fluoro-phenyl)-ethylamine 
• 1421423-89-3 2-(3-chloro-4-fluorobenzyl)-7,8-dimethoxy-3,4-dihydroisoquinolin-1(2H)-one 
• 1366126-78-4 C₁₃H₈Cl₂FN₃O 
• 1335027-53-6 ethyl 2-[(3-chloro-4-fluorophenyl)methyl]-3-cyclobutyl-3-oxopropanoate 
• 1202013-24-8 3-(3-chloro-4-fluorobenzyl)-5-methoxypyrido[3,4-d]pyrimidin-4(3H)-one 
• 915409-45-9 C₂₈H₂₅ClFN₃O₅S 

Relevant articles and documents

Discovery of 3-Pyridyl Isoindolin-1-one Derivatives as Potent, Selective, and Orally Active Aldosterone Synthase (CYP11B2) Inhibitors

Aldosterone synthase (CYP11B2) inhibitors have been explored in recent years as an alternative therapeutic option to mineralocorticoid receptor (MR) antagonists to reduce elevated aldosterone levels, which are associated with deleterious effects on various organ systems including the heart, vasculature, kidney, and central nervous system (CNS). A benzamide pyridine hit derived from a focused screen was successfully developed into a series of potent and selective 3-pyridyl isoindolin-1-ones CYP11B2 inhibitors. Our systematic structure-activity relationship study enabled us to identify unique structural features that result in high selectivity against the closely homologous cortisol synthase (CYP11B1). We evaluated advanced lead molecules, exemplified by compound 52, in an in vivo cynomolgus monkey acute adrenocorticotropic hormone (ACTH) challenge model and demonstrated a superior 100-fold in vivo selectivity against CYP11B1.

Synthesis and Biological Evaluation of 1,2,3-triazole tethered Pyrazoline and Chalcone Derivatives

A series of pyrazoline derivatives and corresponding chalcone intermediates with substituents same as combretastatin-A4(CA-4) conjugated with triazole nucleus has been synthesized and evaluated for their anticancer potential. Sulphorhodamine B(SRB) assay indicated compound 12c to be the most active compound from the series with GI50 value of 6.7 μm against the human liver carcinoma cell line HepG2. Interestingly, the intermediate 11c exhibited more promising cytotoxicity demonstrating GI50 value of 1.3 μm against the prostate cancer cell line DU145. Compounds 11c and 12c caused accumulation of cells in G2/M phase and inhibited tubulin polymerization. Furthermore, these compounds reduce the mitochondrial membrane potential and activate caspases 3 and 9, thereby indicating their ability to trigger apoptosis.

Anti-tubercular agents. Part 8: Synthesis, antibacterial and antitubercular activity of 5-nitrofuran based 1,2,3-triazoles

A series of 5-nitrofuran-triazole conjugates were synthesized and evaluated for their antimicrobial activity against both Gram-positive and Gram-negative bacterial strains. All the compounds exhibited promising inhibition towards Gram-positive pathogenic strains, while mild inhibitory effects were observed towards Gram-negative bacterial strains. Some of the compounds 8a, 8b, 8e, 8f, 8h are most active among the series exhibiting MIC value of 1.17 μg/ml against different bacterial strains. The bactericidal activity is found to be in accordance with the bacterial growth inhibition data. Compound 8e was found to be equipotent to the standard drug Ciprofloxacin displaying MBC value of 1.17 μg/ml against the bacterial strain Bacillus subtilis. The compounds have also demonstrated promising antibacterial activity against the resistant strain MRSA and were found to be effective inhibitors of biofilm formation. The compound 8b exhibited excellent anti-biofilm activity with IC50 value as low as 0.8 μg/ml. These conjugates were also screened for antitubercular activity against Mycobacterium tuberculosis H37Rv strain. Compound 8e showed promising antitubercular activity with MIC value of 0.25 μg/ml. Most of these compounds are less toxic to normal mammalian cells than the widely used antibacterial drug Ciprofloxacin.

NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES

The invention provides novel compounds having the general formula (I) wherein R1, R2, R3, R4? R5, R6, A1, A2, A3, A4, A5 and n are as described herein,compositions including the compounds and methods of using the compounds as aldosterone synthase (CYP11B2 or CYP11B1) inhibitors for the treatment or prophylaxis of chronic kidney disease, congestive heart failure, hypertension, primary aldosteronism and Cushing syndrom.

PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II

Provided herein are phosphadiazine polymerase inhibitor, for example, of any of Formula I, II, III, I′, II′, I″, II″, Ia, IIa, or IIIa, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof.

Indole derivatives and their use as MCP-1 antagonist

A compound of formula (1) wherein R1 is hydrogen, halo or methoxy, R2 is hydrogen, halo, methyl, ethyl or methoxy; R3 is carboxy, tetrazolyl, or —CONHSO2R4where R4is methyl, ethyl, phenyl, 2,5-dimethylisoxazolyl or trifluoromethyl; T is —CH2— or —SO2—; and ring A is 3-chlorophenyl, 4-chlorophenyl, 3-trifluoromethylphenyl, 3,4-dichlorophenyl, 3,4-difluorophenyl, 3-fluoro-4-chlorophenyl, 3-chloro-4-fluorophenyl or 2,3-dichloropyrid-5-yl; or a pharmaceutically acceptable salt or prodrug thereof, as well as pharmaceutical compositions containing them are described and claimed. These compounds and compositions are useful in the treatment of disease mediated by monocyte chemoattractant protein-1 or RANTES (Regulated Upon Activation, Normal T-cell Expressed and Secreted), such as inflammatory disease.